No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CPRX Catalyst Pharmaceuticals
- 14.930
- +0.250+1.70%
Trading Apr 26 12:06 ET
1.76BMarket Cap23.70P/E (TTM)
15.060High14.705Low187.55KVolume14.840Open14.680Pre Close2.80MTurnover0.18%Turnover Ratio23.70P/E (Static)118.01MShares17.76552wk High4.54P/B1.52BFloat Cap11.09052wk Low--Dividend TTM101.78MShs Float22.110Historical High--Div YieldTTM2.42%Amplitude0.370Historical Low14.906Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
20 Companies Screened for Quality in a Cheap -2-
CarGurus Inc. Class A CARG 13.9% 0.0% 28.5% 4.8% 12.0% Inter
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Compa
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Is Largely Controlled by Institutional Shareholders Who Own 65% of the Company
Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Share Price Matching Investor Opinion
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) price-to-earnings (or "P/E") ratio of 26.1x might make it look like a strong sell right now compared to the market in the United States, where around hal
Comments
The absence of insider buying at Catalyst Pharmaceuticals over the past year is concerning. However, the high level of insider ownership indicates alignment with shareholder interests. Insider selling, even below the current price, raises questions about their view on the company's valuation.
Possible Bearish Signals With Catalyst Pharmaceuticals Insiders Disposing Stock 1
Investors are ostensibly keeping Catalyst Pharmaceuticals' P/E high due to expectations of its future growth surpassing the market. Currently, shareholders are confident in future earnings and do not foresee a significant dip in the share price in the near future.
While the level of insider ownership is robust, it is not outstanding. The recent insider selling without any corresponding insider buying over the past three months or the past year signals caution towards the company's stock.
The CEO of Catalyst Pharmaceuticals expressed optimism about the appointment of Michael W. Kalb as new CFO and the promotions, which are expected to drive transformative contributions to the company's short and long-term growth.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg